AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00922766 — intervention group
Intervention type: DRUG
Intervention: Dalteparin
Description: Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention \[PCI\] or coronary artery bypass graft \[CABG\] within 48 hours).
Study NCT02603432 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: 1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
Study NCT02603432 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.
Study NCT02603432 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care
Description: BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.
Study NCT02603432 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Following the planned interim analysis for this study: Avelumab
Description: 1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
Study NCT03071172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone Soft Capsules
Description: Drugs for IVF-ET (in vitro fertilization and embryo transfer).
Study NCT05843526 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental healing abutment
Description: Implant placement (Straumann) Experimental abutment made of titanium, PEEK polyetheretherketone, resin was randomly assessed to the implant site.~Abutment screw channel was filled with Teflon and closed with resin composite. Mouthwash based 0.2% chlorhexidine for 10 days and analgesics (ibuprofen 400 mg, up to 4/d) if necessary.~After 8 weeks, harvesting of the soft tissues around experimental abutment with experimental abutment using a custom-made guide was placed on the experimental abutment
Study NCT00803881 — intervention group
Intervention type: OTHER
Intervention: nasal lavage and sputum collection
Description: non-invasive longitudinal assessment of pathogen colonization in both airway levels
Study NCT04760158 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Exercise
Description: Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks
Study NCT04760158 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks
Study NCT01982955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed was administered at a dose of 500 milligram per square meter (mg/m\^2) as intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
Study NCT04760158 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Participants of this study exercised strengthening and stretching 3 days a week for 6 weeks
Study NCT01735656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute stents
Description: zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
Study NCT01735656 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute stents
Description: zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
Study NCT01903304 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Olive Oil
Description: 3 months intervention
Study NCT01903304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: 3 months intervention
Study NCT03592433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Can PIC
Description: Participants will be shown (on a computer or via email link) a website called I Can PIC. I Can PIC provides health insurance education, suggests ways to learn about the costs of cancer care and follow-up, shows resources to help offset the high costs of care, and helps individuals estimate (based on national data) how much they might spend on health insurance in the upcoming year.
Study NCT02189564 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Feedback about good performance
Study NCT02189564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback about good performance + money
Study NCT02189564 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback about average performance
Study NCT04145895 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Postoperative activity restrictions
Description: Recommendations for return to full activity including return to school, sports, exercise, etc.
Study NCT00889954 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFBeta resistant HER2/EBV-CTLs
Description: Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT).~Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals.
Study NCT04287504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SavvyCheck Vaginal Yeast Test
Description: Point-of-care test for the detection of vaginal candidosis
Study NCT04287504 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: OSOM BVBLUE Test
Description: Point-of-care test for the detection of bacterial vaginosis
Study NCT03442738 — intervention group
Intervention type: PROCEDURE
Intervention: Endocuff group
Description: Endocuff Vision cap on Standard colonoscope
Study NCT00116831 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: oral anti-diabetic medication
Study NCT00116831 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone maleate
Description: oral antidiabetic medication
Study NCT04279665 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Description: 20 minutes of wearing a virtual reality headset with a choice of 4 environments based on their preference and another 20 minutes with a less immersive condition
Study NCT01623869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01623869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trebananib
Description: Given IV
Study NCT00099866 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vildagliptin
Study NCT00099866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Comparator
Study NCT01868334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillar 1: Convenient Vaccination Services
Description: Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond.~Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap.
Study NCT01868334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillar 2: Patient notification
Description: Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, on-hold messages, clinic websites, and/or social media
Study NCT01868334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillar 3: Enhanced Office Systems
Description: Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates
Study NCT01868334 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pillar 4: Motivation
Description: Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
Study NCT03616912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baricitinib
Description: Administered orally.
Study NCT03616912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study NCT04651127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab + Chidamide
Description: In combination dose finding phase, phase 1b will begin with Dose Level 1: chidamide 30 mg/day orally (twice a week) and toripalimab (240mg q3w, intravenously) will be administered to eligible subjects on a 21-day treatment cycle. Two dose de-escalation steps are included: Dose Level 2 (chidamide 25 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously) and Dose Level 3 (chidamide 20 mg/day orally, twice a week and toripalimab 240mg q3w, intravenously). If RP2D was reached in Part A, eligible patients would be enrolled and receive toripalimab (240mg q3w, intravenously) plus chidamide (RP2D, twice a week).
Study NCT04373746 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NICCI
Description: Non-invasive beat-to-beat blood pressure monitor capable of producing a waveform similar to an invasive arterial line.
Study NCT03869879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Feedback-assisted physical therapy
Description: The system uses unobtrusive, wearable, inertial sensors with real-time algorithms to provide real-time feedback on: step time asymmetry, foot clearance, arm swing, trunk lateral range, and foot strike angle during gait.
Study NCT03869879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditional physical therapy
Description: Therapists will treat these patients with traditional therapeutic modalities and practices.
Study NCT02547584 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Catheter ablation
Description: Pulmonary vein antrum isolation (PVAI) plus entire posterior wall plus coronary sinus plus left part of the septum. This intervention will be received by all as standard of care
Study NCT01982955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin was administered at a dose of 75 mg/m\^2 as intravenous infusion over 2 hours on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
Study NCT01982955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin was administered intravenously on Day 1 of each 21-day cycle at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator until progressive disease, intolerable toxicity, participants withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
Study NCT03616912 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT01995695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine
Description: Participants will receive approximately 10\^7.0 focus forming units (FFU) of the live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine. The vaccine will be delivered by an Accuspray nasal spray device (0.25 mL per nostril for a total of 0.5 mL of vaccine).
Study NCT01995695 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated subvirion H7N9 influenza vaccine
Description: Participants will receive 30 mcg of the inactivated subvirion H7N9 vaccine by intramuscular injection.
Study NCT03383328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID + prednisolone, preoperative
Description: Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
Study NCT03383328 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NSAID + prednisolone, postoperative
Description: Ketorolactrometamol 5 mg/ml and prednisolone acetate 1% w/v eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
Study NCT03383328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID, preoperative
Description: Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting 3 days prior to surgery and until 3 weeks after surgery.
Study NCT03383328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAID, postoperative
Description: Ketorolactrometamol 5 mg/ml eye drops are administered 3 times pr. day, starting on the day of surgery and until 3 weeks after surgery.
Study NCT03383328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drop-less surgery
Description: A depot of 0.5 ml Dexamethason Krka 4 mg/ml solution for injection/infusion is administered during cataract surgery.
Study NCT02782416 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Examination of latent tuberculosis
Study NCT02782416 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Examination of latent tuberculosis
Study NCT05843526 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Experimental healing abutment
Description: Implant placement (Straumann) Experimental abutment made of titanium, PEEK polyetheretherketone, resin was randomly assessed to the implant site.~Abutment screw channel was filled with Teflon and closed with resin composite. Mouthwash based 0.2% chlorhexidine for 10 days and analgesics (ibuprofen 400 mg, up to 4/d) if necessary.~After 8 weeks, harvesting of the soft tissues around experimental abutment with experimental abutment using a custom-made guide was placed on the experimental abutment
Study NCT02782416 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Examination of latent tuberculosis
Study NCT04115943 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment protocol for neck pain
Description: The protocol to be used in the study is in accordance with the latest guidelines for the treatment of neck pain associated with limited mobility for patients in the chronic phase. The followed techniques will be performed: i) manual therapy - manipulation or mobilization of the upper cervical spine, manipulation or mobilization of the cervical, cervicothoracic and thoracic regions, manual cervical traction, release of the cervical muscles and muscles of the scapulothoracic region; ii) exercises - strengthening and resistance exercises for the muscles of the scapular girdle, coordination, proprioception and postural training of the cervical and scapulothoracic regions.
Study NCT04115943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment protocol for neck pain
Description: The protocol to be used in the study is in accordance with the latest guidelines for the treatment of neck pain associated with limited mobility for patients in the chronic phase. The followed techniques will be performed: i) manual therapy - manipulation or mobilization of the upper cervical spine, manipulation or mobilization of the cervical, cervicothoracic and thoracic regions, manual cervical traction, release of the cervical muscles and muscles of the scapulothoracic region; ii) exercises - strengthening and resistance exercises for the muscles of the scapular girdle, coordination, proprioception and postural training of the cervical and scapulothoracic regions.
Study NCT04115943 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Protocol for release of tongue muscles
Description: . The aim is the relaxation of the suprahyoid muscles (mylohyoid, geniohyoid, digastric and stylohyoid) as well as the cervical fascia of the anterior region and soft tissues of the region of the pharynx and larynx.
Study NCT02574065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L. reuteri DSM 17938
Description: Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
Study NCT02574065 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: The placebo consists of an identical formulation without L. reuteri DSM 17938
Study NCT01456806 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.
Study NCT01456806 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Education
Description: Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.
Study NCT02022878 — intervention group
Intervention type: PROCEDURE
Intervention: PCI of CTO
Study NCT00993356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preoperative lanreotide treatment
Description: Patients received lanreotide for 16 weeks before the surgical resection \[starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH > 5 mU/L on GH day curve (GHDC)\] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
Study NCT00993356 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transsphenoidal surgery
Study NCT04122040 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roxithromycin 300 MG
Description: Roxithromycin 300 mg oral per day
Study NCT04122040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo one table oral once dialy
Study NCT03935152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dydrogesterone
Description: dydrogesterone capsule
Study NCT01587157 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: capnography
Study NCT01205087 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OKT3
Description: Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.
Study NCT01205087 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: OKT3
Description: Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.
Study NCT01876225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forced coughing during cervical punch biopsy
Study NCT00271401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Angioplasty
Study NCT00271401 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intracoronary Stent
Study NCT00271401 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intracoronary Stent
Study NCT00271401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abxicimab
Study NCT00271401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Study NCT00271401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparin
Study NCT03752658 — intervention group
Intervention type: DRUG
Intervention: Tenofovir Alafenamide
Description: The dose of tenofovir alafenamide (TAF) will be 25mg tablet taken orally once daily with food for 36 months, patients will be treated with TAF alone or in combination with anti-HBV agents
Study NCT04496011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training with cycle ergometer
Description: Patients start with an initial warm-up of 2 minutes, with rotations per minute free, without load. Progressively, the load of the exercise cycle increases every minute up to the supported limit or up to 60% - 70% of maximum heart rate (HRmax). The training will be carried out for 20 continuous minutes, being interrupted whenever the heart rate (HR) reaches 90% of the maximum expected for the age and / or the loss of effort perceived in the BORG scale, above 8 on a scale of 0 to 10.
Study NCT03659877 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity
Description: Participants will undertake a variety of typical daily physical activities, such as laying down, sitting, walking whilst wearing accelerometers and gas analysis equipment.
Study NCT00808548 — intervention group
Intervention type: OTHER
Intervention: counseling, emotional support
Study NCT00808548 — intervention group
Intervention type: OTHER
Intervention: emotional support
Description: emotional support during the interview
Study NCT00808548 — intervention group
Intervention type: OTHER
Intervention: emotional support
Description: emotional supporting during the interview